Compare SoundHound AI Inc (SOUN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs BIO-TECHNE Corp — how do they compare? SoundHound AI Inc trades at $5.59 (market cap $2.50B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 4.5× SoundHound AI Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SoundHound AI Inc for 23 Days and BIO-TECHNE Corp for 63 Days on average.
| SOUN | TECH | |
|---|---|---|
Market Cap | $2.50B | $11.37B |
Volume | 14,612,912 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $21.40 | $72.61 |
52-Week Low | $5.52 | $43.31 |
Typical Hold Time | 23 Days | 63 Days |
Enterprise Value | $2.30B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $5.63, down 1.57% on the day, with bearish technical signals from moving averages but bullish oscillators. The company shows strong revenue growth with 2025 revenue of $168.92M and projected 2026 revenue of $203M, though it remains unprofitable with a -67.45% net income margin. Recent developments include expansion in restaurant and banking sectors with new OASYS Edge technology for embedded voice AI.
While analyst consensus is strongly bullish with a $9.33 price target (75% buy ratings), significant risks include persistent losses, negative cash flow projections for 2026, and insider selling activity. The stock offers substantial upside potential if execution improves but carries high risk until profitability is achieved.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
